{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T23:57:20Z","timestamp":1785023840979,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40268-014-0049-5","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T07:54:25Z","timestamp":1400486065000},"page":"31-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Implications of the 2013 ESH\/ESC Hypertension Guidelines: Targets, Choice of Therapy, and Blood Pressure Monitoring"],"prefix":"10.1007","volume":"14","author":[{"given":"Sverre E.","family":"Kjeldsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonje A.","family":"Aksnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"49_CR1","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/HJH.0b013e3282f0580f","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751\u201362.","journal-title":"J Hypertens"},{"key":"49_CR2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J"},{"key":"49_CR3","doi-asserted-by":"crossref","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","DOI":"10.1001\/jama.2013.284427"},{"key":"49_CR4","doi-asserted-by":"crossref","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertension. 2014;32:3\u201315.","DOI":"10.1097\/HJH.0000000000000065"},{"key":"49_CR5","doi-asserted-by":"crossref","unstructured":"Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. J Hum Hypertens. 1997;11:331\u20132.","DOI":"10.1038\/sj.jhh.1000467"},{"key":"49_CR6","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.","journal-title":"BMJ"},{"key":"49_CR7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","volume":"165","author":"F Turnbull","year":"2005","unstructured":"Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410\u20139.","journal-title":"Arch Intern Med"},{"key":"49_CR8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","volume":"46","author":"P Verdecchia","year":"2005","unstructured":"Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386\u201392.","journal-title":"Hypertension"},{"key":"49_CR9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527\u201335.","journal-title":"Lancet"},{"key":"49_CR10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1161\/HYPERTENSIONAHA.111.187252","volume":"59","author":"H Arima","year":"2012","unstructured":"Arima H, Murakami Y, Lam TH, Kim HC, Ueshima H, Woo J, et al. Effects of pre hypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific region. Hypertension. 2012;59:1118\u201323.","journal-title":"Hypertension"},{"key":"49_CR11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.jhh.1001581","volume":"17","author":"FJ He","year":"2003","unstructured":"He FJ, MacGregor GA. Cost of poor blood pressure control in the UK: 62 000 unnecessary deaths per year. J Hum Hypertens. 2003;17:455\u20137.","journal-title":"J Hum Hypertens"},{"key":"49_CR12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/HJH.0b013e32832aa6b5","volume":"27","author":"A Zanchetti","year":"2009","unstructured":"Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27:923\u201334.","journal-title":"J Hypertens"},{"key":"49_CR13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1056\/NEJM198210143071603","volume":"307","author":"Hypertension Detection and Follow-up Program Cooperative Group","year":"1982","unstructured":"Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in \u201cmild\u201d hypertension: results of the hypertension detection and follow-up program. N Engl J Med. 1982;307:976\u201380.","journal-title":"N Engl J Med"},{"key":"49_CR14","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/01.hjh.0000194120.42722.ac","volume":"23","author":"L Liu","year":"2005","unstructured":"Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157\u201372.","journal-title":"J Hypertens"},{"key":"49_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","volume":"291","author":"Medical Research Council Working Party","year":"1985","unstructured":"Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed). 1985;291:97\u2013104.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"49_CR16","doi-asserted-by":"crossref","first-page":"e1001293","DOI":"10.1371\/journal.pmed.1001293","volume":"9","author":"J Lv","year":"2012","unstructured":"Lv J, Neal B, Ehteshami P, Ninomiya T, Woodward M, Rodgers A, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001293.","journal-title":"PLoS Med"},{"key":"49_CR17","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(04)16456-8","volume":"363","author":"MA Weber","year":"2004","unstructured":"Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049\u201351.","journal-title":"Lancet"},{"key":"49_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/HJH.0b013e32834000be","volume":"29","author":"S Czernichow","year":"2011","unstructured":"Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4\u201316.","journal-title":"J Hypertens"},{"key":"49_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145\u201353.","journal-title":"N Engl J Med"},{"key":"49_CR20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.hjh.0000226212.34055.86","volume":"24","author":"H Arima","year":"2006","unstructured":"Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201\u20138.","journal-title":"J Hypertens"},{"key":"49_CR21","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet. 1998;351:1755\u201362.","journal-title":"Lancet"},{"key":"49_CR22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"49_CR23","unstructured":"Hypertension Canada. Canadian Hypertension Education Program (CHEP) 2013 recommendations. Hypertension Canada. http:\/\/www.hypertension.ca\/chep . Accessed 9 Aug 2013."},{"key":"49_CR24","first-page":"579","volume":"39","author":"LS Liu","year":"2011","unstructured":"Liu LS. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579\u2013615.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"49_CR25","unstructured":"National Institute for Health and Care Excellence. Hypertension: clinical management of primary hypertension in adults (CG127). NICE UK. http:\/\/publications.nice.org.uk\/hypertension-cg127 . Accessed 9 Aug 2013."},{"key":"49_CR26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","volume":"61","author":"RW Schrier","year":"2002","unstructured":"Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086\u201397.","journal-title":"Kidney Int"},{"key":"49_CR27","unstructured":"Tight blood pressure control and risk of macro vascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703\u20133."},{"key":"49_CR28","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1097\/HJH.0b013e3283577bdf","volume":"30","author":"J Cederholm","year":"2012","unstructured":"Cederholm J, Gudbj\u00f6rnsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM, et al. Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II). J Hypertens. 2012;30:2020\u201330.","journal-title":"J Hypertens"},{"key":"49_CR29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","volume":"59","author":"J Redon","year":"2012","unstructured":"Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74\u201383.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"49_CR30","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.2337\/dc11-s244","volume":"34","author":"G Mancia","year":"2011","unstructured":"Mancia G, Grassi G, Zanchetti A. Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: the lower, the better? Diabetes Care. 2011;34(Suppl 2):S304\u20137.","journal-title":"Diabetes Care"},{"key":"49_CR31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1681\/ASN.2008070667","volume":"20","author":"BE Galan de","year":"2009","unstructured":"de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883\u201392.","journal-title":"J Am Soc Nephrol"},{"key":"49_CR32","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782\u20138.","journal-title":"Lancet"},{"key":"49_CR33","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121\u201358.","journal-title":"J Hypertens"},{"key":"49_CR34","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217\u201325.","journal-title":"JAMA"},{"key":"49_CR35","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","volume":"102","author":"B Pitt","year":"2000","unstructured":"Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events: PREVENT Investigators. Circulation. 2000;102:1503\u201310.","journal-title":"Circulation"},{"key":"49_CR36","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","volume":"364","author":"PA Poole-Wilson","year":"2004","unstructured":"Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849\u201357.","journal-title":"Lancet"},{"key":"49_CR37","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1291\/hypres.31.2115","volume":"31","author":"JATOS Study Group","year":"2008","unstructured":"JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115\u201327.","journal-title":"Hypertens Res"},{"key":"49_CR38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","volume":"56","author":"T Ogihara","year":"2010","unstructured":"Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196\u2013202.","journal-title":"Hypertension"},{"key":"49_CR39","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr039","volume":"32","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500\u20138.","journal-title":"Eur Heart J"},{"key":"49_CR40","doi-asserted-by":"crossref","unstructured":"Verdecchia P, Staessen JA, Angeli F, de SG, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525\u20133.","DOI":"10.1016\/S0140-6736(09)61340-4"},{"key":"49_CR41","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/HJH.0b013e32832e9500","volume":"27","author":"A Zanchetti","year":"2009","unstructured":"Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens. 2009;27:1509\u201320.","journal-title":"J Hypertens"},{"key":"49_CR42","first-page":"355","volume":"79","author":"A Bryce","year":"2011","unstructured":"Bryce A, Coca A. Treatment of hypertension: monotherapy or combination therapy. Rev Argent Cardiol. 2011;79:355\u201363.","journal-title":"Rev Argent Cardiol"},{"key":"49_CR43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"49_CR44","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1185\/03007995.2012.729505","volume":"28","author":"SE Kjeldsen","year":"2012","unstructured":"Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin. 2012;28:1685\u201397.","journal-title":"Curr Med Res Opin"},{"key":"49_CR45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","volume":"56","author":"JM Flack","year":"2010","unstructured":"Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780\u2013800.","journal-title":"Hypertension"},{"key":"49_CR46","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","volume":"375","author":"AJ Webb","year":"2010","unstructured":"Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906\u201315.","journal-title":"Lancet"},{"key":"49_CR47","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022\u201331.","journal-title":"Lancet"},{"key":"49_CR48","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417\u201328.","journal-title":"N Engl J Med"},{"key":"49_CR49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1751-7176.2012.00699.x","volume":"14","author":"SA AlGhurair","year":"2012","unstructured":"AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization multidimensional adherence model. J Clin Hypertens (Greenwich). 2012;14:877\u201386.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"49_CR50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005344-200402000-00021","volume":"43","author":"E Kuschnir","year":"2004","unstructured":"Kuschnir E, Bendersky M, Resk J, Panart MS, Guzman L, Plotquin Y, et al. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 2004;43:300\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"key":"49_CR51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00005344-200304000-00010","volume":"41","author":"S Taddei","year":"2003","unstructured":"Taddei S, Omboni S, Ghiadoni L, Caiazza A, Fogari R, Innocenti P, et al. Combination of lisinopril and nifedipine GITS increases blood pressure control compared with single drugs in essential hypertensive patients. J Cardiovasc Pharmacol. 2003;41:579\u201385.","journal-title":"J Cardiovasc Pharmacol"},{"key":"49_CR52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/HJH.0b013e328342ef04","volume":"29","author":"G Mancia","year":"2011","unstructured":"Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens. 2011;29:600\u20139.","journal-title":"J Hypertens"},{"key":"49_CR53","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","volume":"104","author":"SA Hunt","year":"2001","unstructured":"Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996\u20133007.","journal-title":"Circulation"},{"key":"49_CR54","first-page":"3049","volume":"61","author":"NS Skolnik","year":"2000","unstructured":"Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician. 2000;61:3049\u201356.","journal-title":"Am Fam Physician"},{"key":"49_CR55","doi-asserted-by":"crossref","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995\u20131003.","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"49_CR56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","volume":"9","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469\u201380.","journal-title":"Lancet Neurol"},{"key":"49_CR57","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547\u201353.","journal-title":"Lancet"},{"key":"49_CR58","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"49_CR59","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/01.hjh.0000432505.47413.d3","volume":"31","author":"E O\u2019Brien","year":"2013","unstructured":"O\u2019Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on abulatory blood pressure monitoring. J Hypertens. 2013;31:1731\u201368.","journal-title":"J Hypertens"},{"key":"49_CR60","doi-asserted-by":"crossref","first-page":"c1104","DOI":"10.1136\/bmj.c1104","volume":"340","author":"GA Head","year":"2010","unstructured":"Head GA, Mihailidou AS, Duggan KA, Beilin LJ, Berry N, Brown MA, et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ. 2010;340:c1104.","journal-title":"BMJ"},{"key":"49_CR61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/hr.2013.145","volume":"37","author":"G Parati","year":"2014","unstructured":"Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Hypertens Res. 2014;37:187\u201393.","journal-title":"Hypertens Res"},{"key":"49_CR62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/jch.12255","volume":"16","author":"JB Byrd","year":"2014","unstructured":"Byrd JB, Brook RD. Arm position during ambulatory blood pressure monitoring: a review of the evidence and clinical guidelines. J Clin Hypertens (Greenwich). 2014;16:225\u201330.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"49_CR63","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/HJH.0b013e3282f97854","volume":"26","author":"D Conen","year":"2008","unstructured":"Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26:1290\u20139.","journal-title":"J Hypertens"},{"key":"49_CR64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/HJH.0b013e32834e4aed","volume":"30","author":"AM Ward","year":"2012","unstructured":"Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449\u201356.","journal-title":"J Hypertens"},{"key":"49_CR65","doi-asserted-by":"crossref","unstructured":"Segura J, Banegas JR, Ruilope LM. Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: data from the Spanish ABPM registry. Clin Exp Pharmacol Physiol. 2014;41:30\u20136.","DOI":"10.1111\/1440-1681.12126"},{"key":"49_CR66","first-page":"7","volume":"4","author":"E O\u2019Brian","year":"2011","unstructured":"O\u2019Brian E. The value of 24-h blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Top Hypertens. 2011;4:7\u201323.","journal-title":"Hot Top Hypertens"},{"key":"49_CR67","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.clinthera.2004.09.003","volume":"26","author":"P Palatini","year":"2004","unstructured":"Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Vari N, Ferrara R, et al. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. Clin Ther. 2004;26:1436\u201345.","journal-title":"Clin Ther"},{"key":"49_CR68","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.2337\/dcS13-2039","volume":"36","author":"E Grossman","year":"2013","unstructured":"Grossman E. Ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Diabetes Care. 2013;36:S307\u201311.","journal-title":"Diabetes Care"},{"key":"49_CR69","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(11)61184-7","volume":"378","author":"K Lovibond","year":"2011","unstructured":"Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet. 2011;378:1219\u201330.","journal-title":"Lancet"},{"key":"49_CR70","doi-asserted-by":"crossref","unstructured":"Radchenko G, Sirenko Y, Polischuk S. Home self measurement monitoring of blood pressure: relation to office and ambulatory blood pressure measurement. J Hypertens. 2010;28:14\u201315.","DOI":"10.1097\/01.hjh.0000378941.26545.d6"},{"key":"49_CR71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.184184","volume":"59","author":"P Palatini","year":"2012","unstructured":"Palatini P. Ambulatory and home blood pressure measurement: complementary rather than competitive methods. Hypertension. 2012;59:2\u20134.","journal-title":"Hypertension"},{"key":"49_CR72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2261-13-21","volume":"13","author":"C O\u2019Brien","year":"2013","unstructured":"O\u2019Brien C, Bray EP, Bryan S, Greenfield SM, Haque MS, Hobbs FD, et al. Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial. BMC Cardiovasc Disord. 2013;13:21.","journal-title":"BMC Cardiovasc Disord"},{"key":"49_CR73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/HYPERTENSIONAHA.111.00690","volume":"62","author":"G Mancia","year":"2013","unstructured":"Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168\u201374.","journal-title":"Hypertension"},{"key":"49_CR74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1749-6632.2012.06489.x","volume":"1254","author":"RA Phillips","year":"2012","unstructured":"Phillips RA. Controversies in blood pressure goal guidelines and masked hypertension. Ann N Y Acad Sci. 2012;1254:115\u201322.","journal-title":"Ann N Y Acad Sci"},{"key":"49_CR75","unstructured":"International Society for Chronobiology, American Association of Medical Chronobiology and Chronotherapeutics, Spanish Society of Applied Chronobiology CaVR, Spanish Society of Atherosclerosis, Romanian Society of Internal Medicine, Hermida RC, et al. Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30:355\u2013410."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-014-0049-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0049-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:30Z","timestamp":1551204750000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-014-0049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s40268-014-0049-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,20]]}}}